Novartis

News

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f

News

ASCO: Novartis touts Kisqali adjuvant breast cancer data

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte

News

Cosentyx nod ends 10-year drought in new biologics for HS

Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following i

News

Novartis buys Pharming priority review voucher for a song

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate.

News

EU approval for Novartis’ sickle cell drug set to be pulled

Novartis has said it is “disappointed” that the EMA’s Human Medicines Committee has recommended revoking the conditional EU approval for sickle cell disease (SCD) therapy

News

Roche’s BTK drug fenebrutinib hits the mark in MS

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

ASCO: Novartis touts Kisqali adjuvant breast cancer data

Cosentyx nod ends 10-year drought in new biologics for HS

Novartis buys Pharming priority review voucher for a song

EU approval for Novartis’ sickle cell drug set to be pulled

Roche’s BTK drug fenebrutinib hits the mark in MS

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

Novartis

Editor's Picks